Limits...
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.

Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR - Int. J. Clin. Pract. (2007)

Bottom Line: Mean KHQ scores decreased significantly (p<or=0.0196) from baseline to study end in eight of 10 domains, indicating improved health-related quality of life.Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.Oxybutynin transdermal system treatment of men with OAB was effective and well tolerated, regardless of history of prostate condition.

View Article: PubMed Central - PubMed

Affiliation: Weill Medical College of Cornell University, New York, NY 10021, USA. das2021@med.cornell.edu

ABSTRACT

Aims: Overactive bladder (OAB) is common in men and may exist concomitantly with benign prostatic hyperplasia (BPH) and obstruction. We present a subanalysis of results from men with OAB in a 6-month, open-label study of treatment with the oxybutynin transdermal system (OXY-TDS). Broad entry criteria were incorporated to yield a clinically representative population.

Methods: All participants received OXY-TDS 3.9 mg/day. Effectiveness was assessed by changes in scores on validated questionnaires, which included the single-item Patient Perception of Bladder Condition (PPBC), the King's Health Questionnaire (KHQ) and the Beck Depression Inventory-II (BDI-II).

Results: The proportion of men (n=369; mean age=69.6 years) who reported that their bladder condition caused moderate, severe or many severe problems (PPBC>or=4) improved from 77.3% at baseline to 38.1-53.6% in subsequent months. Mean KHQ scores decreased significantly (p12 (associated with a diagnosis of depression) decreased from 23.9% to 17.9% (p=0.0055). Men with a history of 'prostate problems' or use of 'BPH medication' (32.2%) had KHQ domain changes that were similar (p>or=0.1016) to those of other men. Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.

Conclusions: Oxybutynin transdermal system treatment of men with OAB was effective and well tolerated, regardless of history of prostate condition.

Show MeSH

Related in: MedlinePlus

Participant-reported satisfaction with oxybutynin transdermal system (OXY-TDS) treatment; percentages are calculated on the basis of the total number of respondents at each evaluation. (A) Overall satisfaction in the total population of male participants. (B) Overall satisfaction in male participants who had been treated before for overactive bladder (OAB)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2228367&req=5

fig05: Participant-reported satisfaction with oxybutynin transdermal system (OXY-TDS) treatment; percentages are calculated on the basis of the total number of respondents at each evaluation. (A) Overall satisfaction in the total population of male participants. (B) Overall satisfaction in male participants who had been treated before for overactive bladder (OAB)

Mentions: Most male participants (61.6–71.3%) were ‘very satisfied’ or ‘satisfied’ with OXY-TDS throughout the study (Figure 5A). Conversely, a low proportion (8.6–15.4%) were ‘dissatisfied’ or ‘very dissatisfied’ (Figure 5A). Similar results were obtained for questions about convenience, effectiveness and tolerability of the patch (data not shown). Most male participants who had been treated previously for OAB (54.7–60.6%) said that the patch offered significant or some benefits over previous treatments, suggesting that they preferred the patch over their prior therapy (Figure 5B). A small proportion preferred their previous medications (7.2–12.8%). Similar opinions of the patch vs. prior therapy were reported with respect to ease of use, effectiveness and tolerability (data not shown).


Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.

Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR - Int. J. Clin. Pract. (2007)

Participant-reported satisfaction with oxybutynin transdermal system (OXY-TDS) treatment; percentages are calculated on the basis of the total number of respondents at each evaluation. (A) Overall satisfaction in the total population of male participants. (B) Overall satisfaction in male participants who had been treated before for overactive bladder (OAB)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2228367&req=5

fig05: Participant-reported satisfaction with oxybutynin transdermal system (OXY-TDS) treatment; percentages are calculated on the basis of the total number of respondents at each evaluation. (A) Overall satisfaction in the total population of male participants. (B) Overall satisfaction in male participants who had been treated before for overactive bladder (OAB)
Mentions: Most male participants (61.6–71.3%) were ‘very satisfied’ or ‘satisfied’ with OXY-TDS throughout the study (Figure 5A). Conversely, a low proportion (8.6–15.4%) were ‘dissatisfied’ or ‘very dissatisfied’ (Figure 5A). Similar results were obtained for questions about convenience, effectiveness and tolerability of the patch (data not shown). Most male participants who had been treated previously for OAB (54.7–60.6%) said that the patch offered significant or some benefits over previous treatments, suggesting that they preferred the patch over their prior therapy (Figure 5B). A small proportion preferred their previous medications (7.2–12.8%). Similar opinions of the patch vs. prior therapy were reported with respect to ease of use, effectiveness and tolerability (data not shown).

Bottom Line: Mean KHQ scores decreased significantly (p<or=0.0196) from baseline to study end in eight of 10 domains, indicating improved health-related quality of life.Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.Oxybutynin transdermal system treatment of men with OAB was effective and well tolerated, regardless of history of prostate condition.

View Article: PubMed Central - PubMed

Affiliation: Weill Medical College of Cornell University, New York, NY 10021, USA. das2021@med.cornell.edu

ABSTRACT

Aims: Overactive bladder (OAB) is common in men and may exist concomitantly with benign prostatic hyperplasia (BPH) and obstruction. We present a subanalysis of results from men with OAB in a 6-month, open-label study of treatment with the oxybutynin transdermal system (OXY-TDS). Broad entry criteria were incorporated to yield a clinically representative population.

Methods: All participants received OXY-TDS 3.9 mg/day. Effectiveness was assessed by changes in scores on validated questionnaires, which included the single-item Patient Perception of Bladder Condition (PPBC), the King's Health Questionnaire (KHQ) and the Beck Depression Inventory-II (BDI-II).

Results: The proportion of men (n=369; mean age=69.6 years) who reported that their bladder condition caused moderate, severe or many severe problems (PPBC>or=4) improved from 77.3% at baseline to 38.1-53.6% in subsequent months. Mean KHQ scores decreased significantly (p12 (associated with a diagnosis of depression) decreased from 23.9% to 17.9% (p=0.0055). Men with a history of 'prostate problems' or use of 'BPH medication' (32.2%) had KHQ domain changes that were similar (p>or=0.1016) to those of other men. Most men (76.2%) reported no treatment-related adverse events; two men (0.5%) experienced symptoms of mild urinary retention, but neither required catheterisation.

Conclusions: Oxybutynin transdermal system treatment of men with OAB was effective and well tolerated, regardless of history of prostate condition.

Show MeSH
Related in: MedlinePlus